AI tool for NASH diagnosis receives first EMA qualification
The European Medicines Agency has qualified the first artificial intelligence-based tool designed to evaluate liver biopsies in patients with metabolic dysfunction-associated steatohepatitis (MASH). The system, called AIM-NASH, helps pathologists assess disease severity and reduce variability in histological scoring, with the aim of accelerating drug development for this increasingly common liver condition.